A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Clinical trial NCT02703272 · TERMINATED
Trial details
- NCT number
- NCT02703272
- Sponsor
- Janssen Research & Development, LLC
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-01
- Primary completion
- 2021-06-11
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.